Vision and mission

Vision

Leaving no one behind with immunisation

Mission

To save lives and protect people’s health by increasing equitable and sustainable use of vaccines

Mission indicators

Under-five child mortality reduction
Future deaths averted
(including disaggregated for climate-sensitive diseases)
Future DALYs averted
Reduction in zero-dose children​Children immunised ​Economic benefits unlocked

Principles

Gavi 6.0’s strategic framework includes ten principles, intended to define the Vaccine Alliance’s characteristics, its business model and its aspirations – such as being country-led and sustainable as well as community-owned and inclusive, making zero-dose and missed communities its first priority, being gender-focused, or being innovative, collaborative and accountable:

  • Country-led, sustainable

    Country-led, sustainable

    Bolster country leadership to sustainably finance and deliver immunisation.

    This principle signals the importance of country-led approaches in Gavi 6.0, including in priority setting for immunisation.

  • Community-owned, inclusive

    Community-owned, inclusive

    Engage communities and civil society organisations in planning, implementation and oversight of immunisation.

    This principle signals the importance of community engagement in Gavi 6.0, including in priority setting for immunisation.

  • Zero-dose and missed communities,
    first priority

    Zero-dose and missed communities, first priority

    Prioritise children missing out on vaccination, including among migrants, displaced and other vulnerable populations.

    This principle signals Gavi’s core focus on the equity agenda, further described under strategic goal 1. It will remain Gavi’s core programmatic priority.

  • Gender-focused

    Gender-focused

    Identify and address gender-related barriers to promote immunisation equity.

    Building on the learnings from Gavi 5.1, the Alliance will continuously enhance its approach to gender-responsive programming and gender equity.

  • Differentiated, fragility-responsive

    Differentiated, fragility-responsive

    Target and tailor support to regional, national and subnational needs, including fragile, conflict and humanitarian contexts.

    The Alliance will further differentiate interventions – prioritising, targeting and tailoring to specific national and sub-national contexts through each phase of the transition out of Gavi support.

 

  • Integrated

    Integrated

    Strengthen integration of immunisation and primary health care to reach missed communities in support of Universal Health Coverage.

    This principle speaks to the importance of integrated approaches for the Alliance’s equity agenda; and Gavi’s contribution to more resilient, equitable, people-centred and sustainable health systems in support of Universal Health Coverage and in alignment with the Lusaka Agenda.

  • Adaptive, resilient

    Adaptive, resilient

    Help countries leverage immunisation to address the challenges of global health security, antimicrobial resistance and other major global issues.

    The Alliance will continue to: (a) support countries to introduce and scale up vaccines to prevent outbreaks, and to procure diagnostics to detect and contain them; (b) ensure vaccine availability at the onset of outbreaks; and (c) foster a coalition of partners to prepare for and coordinate outbreak response activities.

  • Climate-sensitive

    Climate-sensitive

    Support countries to adapt to the consequences of climate change and mitigate the carbon footprint of the Alliance.

    This principle was newly added in Gavi 6.0. The Alliance will mainstream climate change considerations into its investments and engagement across the four strategic goals.

  • Innovative

    Innovative

    Identify and scale up innovative products, practices and services to support Gavi’s goals.

    Gavi will continue to support new products, practices and services to enhance immunisation efficiency and effectiveness in alignment with Gavi’s mission and country needs.

  • Collaborative, accountable

    Collaborative, accountable

    Accelerate purposeful partnerships with regional and global health institutions to collectively and efficiently respond to countries’ needs.

    Gavi 6.0 will see an increased role of regional institutions like Africa CDC and the African Union Commission; and will continue to accelerate greater, purposeful collaboration with Global Health Initiatives both within and beyond the immunisation sector, in line with the Lusaka Agenda.

Goals and objectives

Gavi 6.0, the Alliance’s 2021–2025 strategy has four goals, each of them supporting the Alliance’s mission to save lives and protect people’s health by increasing equitable and sustainable use of vaccines. The four goals are:

1. Introduce and scale up vaccines

Gavi 6.0 will provide access to the widest, most innovative portfolio of critical life-saving vaccines ever. The Alliance will support countries vaccinate >500 million more children and adolescents, saving 8-9 million more lives, including 1.5 million through the HPV vaccine.

Gavi will prioritise three main objectives for the introduction and scaling up of vaccines:

  1. Strengthen countries’ prioritisation and optimisation of vaccine programmes, appropriate to their context

    The Alliance will offer a wider range of vaccines in a fiscally constraint environment. It will be critical to support countries optimise their existing vaccine portfolios and prioritise and target the introduction and scale up vaccines that are most appropriate for their local context, capacity and based on evidence.
     
  2. Support countries to introduce and scale up vaccines for prevention of endemic, epidemic and pandemic diseases including beyond infancy

    With the approval of the new Vaccine Investment Strategy in 2024, Gavi will provide access to vaccines against 20+ diseases, including several climate-sensitive ones such as Dengue. In particular, a new Tuberculosis vaccine is expected by the end of Gavi 6.0. It will require preparatory work to ensure readiness for rollout to reach the target age group, typically unserved by routine health services in most Gavi-eligible countries. Efficient, timely and targeted preventative campaigns will continue to be an essential part of the toolkit to prevent outbreaks and epidemics.
     
  3. Ensure equitable and timely access to mechanisms to respond to outbreaks, epidemics, and pandemics

    Gavi will deepen its engagement in responding to outbreaks, epidemics, and pandemics of vaccine-preventable diseases (VPDs), whose risks are continuously rising. This includes: 
    • Expand global vaccine stockpiles (e.g. for measles, typhoid, diphtheria, but also newer vaccines in the Gavi portfolio such as mpox and hepatitis E)
    • Provide market shaping and procurement support to improve and accelerate detection and decision-making on preventative vaccination and outbreak response (through the diagnostic procurement mechanism programme)
    • Support timely intervention by working with an agile coalition of partners and providing surge funding through the First Response Fund and the Day Zero Financing Facility

2. Strengthen health systems to increase equity in immunisation

Increasing equity in immunisation delivery will remain central to Gavi’s next strategy, which aims to contribute to the Immunisation Agenda 2030’s ambition to reduce the number of ‘zero-dose’ children by 50%.

To achieve this, Gavi will focus on three main objectives for strengthening health systems:

  1. Enable countries to extend immunisation to zero-dose children and missed communities, integrated with primary health care, including through addressing gender-related barriers and building resilient demand

    Reaching zero-dose children and missed communities will remain at the heart of the Gavi’s strategy. Gavi will intensify efforts to work with other funders and health programmes to reach and integrate zero-dose investments with broader primary healthcare (PHC) programmes and ensure investments in immunisation can serve as a foundation to deliver other critical PHC services to these communities, and contribute to Universal Health Coverage..
     
  2. Ensure all children are fully immunised by maintaining and strengthening routine immunisation with vaccines required through second year of life

    While Gavi 6.0 will place a strong focus on extending health systems to reach zero-dose children, it will be equally important to ensure these children, once reached, are fully immunised. The Alliance will focus on fully vaccinating children through their second year of life, particularly in missed communities. This approach is crucial for maximizing immunisation benefits, controlling measles, and successfully delivering newer vaccines like those against malaria.
     
  3. Support countries to adapt systems to routinely deliver vaccines to populations outside early childhood through targeted and catalytic interventions

    The Alliance will also help countries adapt their systems to routinely deliver vaccines to populations outside early childhood (i.e. beyond second year of life) through targeted and catalytic interventions, especially guidance, advocacy, technical assistance and partnerships with others. It will offer target and catalytic support, to include guidance, advocacy, technical assistance and partnerships. 

3. Improve programmatic and financial sustainability of immunisation programmes

Gavi does not just help countries expand their national immunisation programmes. It also aims to make immunisation sustainable both financially and programmatically, ensuring countries can sustain their immunisation programmes after Gavi support ends.

To support the sustainability of immunisation programmes, the Alliance will prioritise three main objectives:

  1. Strengthen regional, national and subnational political and social commitment to immunisation, including through increased domestic public resources

    The Alliance will focus on financial sustainability by encouraging countries to invest domestic resources in co-financing Gavi-supported vaccine programmes and other investments to successfully transition out of Gavi’s support. In response to the evolving context, including a deteriorating macro-economic outlook, Gavi will enhance its eligibility, co-financing and transition model to ensure appropriate acceleration of countries’ co-financing obligations and reduce the risk of unsuccessful transitions. Learn more about Gavi 6.0 eligibility, transition and co-financing policies.
     
  2. Ensure sustainable transition through stronger capacity of eligible countries to maintain immunisation performance

    In the next strategic period, Gavi will take a more deliberate approach to programmatic sustainability, helping countries maintain immunisation performance, improve efficiency, and bolster resilience. Recognizing that programmatic sustainability can be challenging as countries transition out of Gavi support, the Alliance will decouple programmatic support from vaccine support for those facing programmatic challenges and allow programmatic support post vaccine transition. 
     
  3. Engage self-financing countries to maintain performance and catalyse critical vaccine introductions

    Gavi will address inequities in access of vaccines in a sub-set of Former- and Never-Gavi-eligible countries and protect Gavi’s investments by mainstreaming the middle-income countries approach into a new ‘Catalytic phase’ post-transition. The support to countries will aim to catalyse new introductions and improve immunisation outcomes in a subset of Former and Never Gavi-eligible countries.

4. Ensure healthy markets for vaccines and related products

The Alliance market shaping model will remain central in 6.0 to foster a sustainable, competitive supplier base, healthy demand, and an environment that encourages innovation.

The Alliance will prioritise three main objectives to ensure healthy markets:

  1. Drive healthy vaccine markets for Gavi- supported and self-financing countries, including acceleration of access to new high-impact, affordable vaccines and delivery innovations 

    The Alliance will continue to evolve its market-shaping efforts to mitigate risks of supply disruptions and monitor healthy market dynamics, ultimately benefitting global markets beyond Gavi-eligible countries. Accelerating access to new and affordable high-impact vaccines and delivery innovations will continue to be a core part of the Alliance’s market shaping agenda in Gavi 6.0. The Secretariat will continue to coordinate closely with partners to ensure access to delivery innovations that can help increase equity and efficiency, including supporting deploy measles and rubella micro-array patches. 
     
  2. Enhance regional vaccine supply security, in support of regional manufacturing expansion ambitions

    Gavi 6.0 will see a substantial contribution from the Alliance towards the enhancement of regional vaccine supply security, with a focus on Africa. As parts of these efforts, Gavi is launching the African Vaccine Manufacturing Accelerator (June 2024). This considerable commitment by Gavi aligns directly with commitments at the highest levels of African country governments, to establish industrial capacities on the African continent for both pandemic response and routine immunisation.
     
  3. Develop sustainable markets for vaccines against outbreak, epidemic, and pandemic-prone diseases

    The Alliance will use its comparative advantage in market-shaping to improve market conditions for vaccines against outbreak and epidemic-prone diseases. The Alliance will work to ensure the sustainability of markets for existing vaccines while continuing to work closely with CEPI and other funders to monitor progress on the pipeline of new outbreak vaccines.

Enablers

  • Secure long-term predictable funding for Gavi programmes

    In line with Gavi’s five-year funding cycles, long-term predictable funding is critical for the Alliance to deliver on its mission.

  • Deliver as one Alliance with strengthened accountability mechanisms

    Gavi will further develop its approach to clearly delineate roles and responsibilities between Alliance partners based on their comparative advantages at global, regional and country levels; improve the culture, capacity and ways of working of the Alliance; and strengthen mutual accountability mechanisms to drive efficiency and performance.

  • Ensure global political commitment for immunisation and global health security

    This enabler signals the importance of the Alliance’s engagement at global level to drive financial and non-financial support for the Alliance’s agenda, while promoting prevention and integration with primary health care.

  • Ensure simple, efficient and agile Gavi operating model

    This new enabler reflects the anticipated streamlining of the Secretariat’s operating model in Gavi 6.0 to better meet the needs of countries. Key changes could include grounding Gavi funding to countries’ national strategies; consolidating Gavi’s cash-based funding into a single envelope focusing on immunisation delivery outcomes; and reforming grant management.

  • Drive digitalisation (including artificial intelligence), improved data and evidence

    This enabler reflects the relevance of new digital technologies and data to drive immunisation outcomes in Gavi 6.0, based on evidence-based decision making.

  • Leverage the private sector and development finance institutions,
    including through innovative finance mechanisms

    This enabler builds on Gavi’s 20-year track record of leveraging innovative finance to achieve the Alliance's goals. In Gavi 6.0, this will continue through the International Finance Facility for Immunisation (IFFIm); increased lending and financing with multilateral development banks; and significantly enhanced private sector resource mobilisation.

Gavi 6.0 one-pager (2026–2030)

The journey to design Gavi 6.0

  • The process of designing Gavi 6.0 was led by the Gavi Board, with strong ownership of Gavi’s Chief Executive Officer (CEO) and Senior Leadership Team.
  • Gavi 6.0 design was based on a highly consultative process. The Alliance’s 2026–2030 strategy design relied on extensive consultations with implementing country representatives, donor governments, core Alliance partners including the World Health Organization, UNICEF and the World Bank, as well as representatives from the vaccine industry, technical agencies, civil society and other private sector partners.

The design of Gavi 6.0 followed three main phases, each involving key touchpoints with the Gavi Board. Following the Board’s approval in June 2024, a final phase focuses on operationalising the new strategy:

Gavi 6.0 phases

ExploreIdentifyFinaliseOperationalise

The design of Gavi 6.0 concluded in June 2024. This leaves 18 months to complete the execution of the Gavi 5.0/5.1 agenda; and prepare to implement the key shifts emerging from Gavi 6.0 from day one.

Gavi 6.0 Alliance Workshop

In late February 2024, Gavi convened a broad consultation in Togo, bringing together over 120 representatives from implementing country governments, civil society organisations, and core and expanded Alliance partners.

Read the recommendations

The event marked a significant milestone in the country-centric design process for Gavi 6.0 ahead of a Gavi Board retreat in April 2024.

Phase 1: global trends, vision and opportunities

The design of Gavi 6.0 started by exploring global trends and their implications for the future global health landscape. This enabled a vision to start taking shape for Gavi 6.0 that identified high-level opportunities for impact and enablers for success. These trends were then assessed based on available evidence, impact data and opinions collected during consultations with the global health community.

Global trends shaping the global health landscape and Gavi’s agenda

  • Promise of new vaccines
  • Growing inequities and renewed focus on primary health care (PHC) and Universal Health Coverage (UHC)
  • Deteriorating macro-economic outlook
  • Spotlight on pandemic prevention, preparedness and response (PPPR)
  • Climate emergency
  • Innovation in immunisation
  • Fragility as the new normal in lower middle-income countries (MICs)
  • Country ownership, regionalisation and global collaboration

Emerging priorities for Gavi 6.0

Emerging priorities for Gavi 6.0

Phase 2: strategic options and initial trade-offs

Phase 2 aimed to identify high-level options for each opportunity for impact and surface trade-offs, to support the Gavi Board in making strategic choices about Gavi’s priorities for the next strategic cycle. Assessment of different options was based on expected health impact and financial implications; key inputs emerged from:

  • forecast models across different opportunities explored and strategic options assessed; and
  • consultations with representatives from Gavi implementing country governments, Alliance partners in Gavi implementing countries and civil society organisations, culminating in a workshop bringing together over 120 representatives in Lomé, Togo, at the end of February – see video above.

Phase 3: final choices and framework

At its retreat in April 2024, the Gavi Board discussed different strategic options and made trade-offs based on estimated health impact and financial implications (costs) – with the goal to design a strategy that would be ambitious for the Alliance, while still realistic in terms of resources needed to deliver on it. Based on the Board’s guidance, concrete strategic options were selected and brought together in the final Gavi 6.0 strategy; and summarised in a one-page framework and an accompanying narrative document. In June 2024, the Board reviewed and approved the Gavi 6.0 strategy and endorsed the proposed approach to operationalise Gavi 6.0.

Last updated: 11 Jul 2024

Subscribe to our newsletter